Trial intelligence / Profile preview

Phase 2 study of selpercatinib in advanced RET-altered solid tumors

CTR20192716Phase 2Active

Sponsor

Eli Lilly and Company

Start

Apr 2020

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1